Evidence map›Paper›PMID 41806061›Full record

ReviewArchives of virology2026

Research progress of nucleocapsid protein of novel coronavirus: structure, function and targeted therapy.

Xie Moyue, Shen Liang, Xia Ying, Yang Yang, Zhan Dongang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Archives of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xie MoyueHubei University of Arts and Science Affiliated Hospital Xiangyang Central Hospital, Xiangyang, Hubei, 441021, China.
Shen LiangCentral Laboratory, Xiangyang Central Hospital Affiliated to Hubei University of Arts and Science, Xiangyang, 441021, Hubei, China.
Xia YingCentral Laboratory, Xiangyang Central Hospital Affiliated to Hubei University of Arts and Science, Xiangyang, 441021, Hubei, China.
Yang YangShenzhen Key Laboratory of Pathogen and Immunity, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital, National Clinical Research Center for infectious disease, Southern University of Science and Technology, Shenzhen, 518020, China.
Zhan DongangOffice of Infection and Control, Xiangyang Central Hospital, Hubei University of Arts and Science, Jingzhou Street 39, Xiangcheng District, Xiangyang, Hubei, 441021, China. 50275@hbuas.edu.cn.

Funding

National Natural Science Foundation of China National Natural Science Foundation of China
6 · The paper itself

Abstract

The outbreak of COVID-19 caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). SARS-CoV-2 poses an ongoing threat to global public health security. The continuous evolution of viruses (e.g., Delta, Omicron) has increased the risk of viral transmissibility, infectivity, and the risk of immune escape. As highly conserved structural proteins of viruses, nucleocapsid proteins (N proteins) play a central role in the viral life cycle, and the study of their functional mechanisms and targeted therapeutics is crucial for the development of antiviral strategies. In this paper, we systematically describe the structural characterization, functional mechanism, and targeted therapy of the SARS-CoV-2 N protein, analyze its key roles in viral packaging, replication, and immune escape, and discuss the challenges and future directions of drug development for the N protein.

Indexed as

Coronavirus Nucleocapsid ProteinsNucleocapsid ProteinsAntiviral AgentsCOVID-19HumansImmune EvasionPandemicsPhosphoproteinsSARS-CoV-2Virus AssemblyVirus ReplicationAntiviral AgentsCoronavirus Nucleocapsid Proteinsnucleocapsid phosphoprotein, SARS-CoV-2Nucleocapsid ProteinsPhosphoproteinsImmunity escapeNovel coronavirusNucleocapsid proteinTargeted therapy

Identifiers

PMID41806061

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.